A new study by Mount Sinai researchers reveals how psychedelics target a specific serotonin receptor, 5-HT1A, to potentially treat disorders like depression without causing hallucinations. Their discovery opens the door to developing non-hallucinogenic psychedelic-based medications.have revealed intricate details on how some psychedelic drugs interact with serotonin receptors, triggering potential therapeutic effects in treating neuropsychiatric conditions like depression and anxiety.
“We were able to fine-tune the 5-MeO-DMT/serotonin scaffold to obtain the maximum activity at the 5-HT1A interface and minimal activity at 5-HT2A,” explains senior author Daniel Wacker, PhD, Assistant Professor of Pharmacological Sciences and Neuroscience at Icahn Mount Sinai. “Our findings suggest that receptors other than 5-HT2A not only modulate behavioral effects stemming from psychedelics, but may substantially contribute to their therapeutic potential.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SciTechDaily1 - 🏆 84. / 68 Read more »